- Home
- CGEN vs NVCT Comparison
CGEN vs NVCT Comparison
Compare CGEN & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- NVCT
- Stock Information
- Founded
- CGEN 1993
- NVCT 2020
- Country
- CGEN Israel
- NVCT United States
- Employees
- CGEN N/A
- NVCT N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- CGEN Health Care
- NVCT Health Care
- Exchange
- CGEN Nasdaq
- NVCT Nasdaq
- Market Cap
- CGEN 167.4M
- NVCT 152.3M
- IPO Year
- CGEN 2000
- NVCT 2022
- Fundamental
- Price
- CGEN $1.43
- NVCT $6.43
- Analyst Decision
- CGEN
- NVCT Strong Buy
- Analyst Count
- CGEN 0
- NVCT 3
- Target Price
- CGEN N/A
- NVCT $15.33
- AVG Volume (30 Days)
- CGEN 217.0K
- NVCT 234.2K
- Earning Date
- CGEN 08-06-2025
- NVCT 08-05-2025
- Dividend Yield
- CGEN N/A
- NVCT N/A
- EPS Growth
- CGEN N/A
- NVCT N/A
- EPS
- CGEN N/A
- NVCT N/A
- Revenue
- CGEN $22,144,000.00
- NVCT N/A
- Revenue This Year
- CGEN N/A
- NVCT N/A
- Revenue Next Year
- CGEN $105.77
- NVCT N/A
- P/E Ratio
- CGEN N/A
- NVCT N/A
- Revenue Growth
- CGEN N/A
- NVCT N/A
- 52 Week Low
- CGEN $1.13
- NVCT $4.44
- 52 Week High
- CGEN $2.66
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- CGEN 37.47
- NVCT 39.18
- Support Level
- CGEN $1.43
- NVCT $6.18
- Resistance Level
- CGEN $1.53
- NVCT $6.99
- Average True Range (ATR)
- CGEN 0.06
- NVCT 0.50
- MACD
- CGEN 0.00
- NVCT -0.03
- Stochastic Oscillator
- CGEN 44.44
- NVCT 31.18
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.